Daiichi Sankyo Co Ltd (OTCPK:DSKYF)
$ 29.3 -1.8 (-5.79%) Market Cap: 57.36 Bil Enterprise Value: 50.88 Bil PE Ratio: 33.41 PB Ratio: 5.36 GF Score: 93/100

Daiichi Sankyo Co Ltd R&D Day (English, Japanese) Transcript

Dec 17, 2019 / 06:30AM GMT
Release Date Price: $22.5
Sunao Manabe
Daiichi Sankyo Company, Limited - President, Group CEO & Representative Director

[Interpreted] I'm Manabe, President and CEO of Daiichi Sankyo. Thank you very much for participating in Daiichi Sankyo's R&D Day despite your very busy schedule at the end of the year.

Today, I will first explain the strengths of Daiichi Sankyo's R&D and share some top line strategic direction for the future. Following my presentation, Junichi Koga, our Global R&D Head, will explain our R&D strategies; and then Antoine Yver, our Global Oncology R&D Head, will provide an update on the status of our R&D in the Oncology area and our future plans.

First, I'd like to talk about the emphasis I place on our R&D. I believe that the strength of our R&D comes from leveraging the combined science and technology capabilities from across the organization. There are 3 sources. The first source is our in-house drug creation capabilities cultivated over the many years. Since our founding more than 100 years ago, Daiichi Sankyo has developed innovative pharmaceuticals as a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot